Skip to main content

Advertisement

SpringerLink
Log in

Bone health-related factors and the use of bisphosphonates in community setting—15-year follow-up study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

The present study investigated the bone health related factors that were associated with the use of bisphosphonates (BP) among 2,050 postmenopausal Finnish women. Low BMD + low trauma energy fracture was the strongest determinant of BP use, while other secondary causes of osteoporosis were less strongly related with BP use. BP use was associated with reduced femoral neck (FN) and lumbar spine (LS) bone loss rate.

Introduction

The aim was to identify bone health related factors associated with the use of BP in a community setting.

Methods

A population-based sample of 2,050 Finnish postmenopausal women was measured with dual X-ray absorptiometry at the FN and LS in 1989, 1994, 1999 and 2004, and information on osteoporosis risk factors, including low-trauma energy fractures, were collected with postal inquiries. Self-reported use of BP in 2004 was considered as the end point variable.

Results

Among BP users, 12% had T-score > −2.0 SD and no fracture during follow-up (FU). In women without any bone medication, 26% had T-score < −2.0 SD or low-trauma energy fracture or both during the FU. In BP users, a significant reduction in FN and LS bone loss rate, cumulative with duration of use, was observed in ANCOVA (p < 0.001). Among BP users, there was a significantly higher proportion of women with several independent risk factors for osteoporosis and more spine and humerus fractures but less ankle fractures. T-score < −2 SD combined with low-trauma energy fracture was significantly related to the use of BPs (p < 0.001, OR = 15.96) and T-score < −2 SD was a stronger predictor of BP use (p < 0.001, OR = 13.29) than fracture (p > 0.05, OR = 1.35) in multivariate logistic regression. Other factors related with BP use were vitamin D use (p = 0.001, OR = 2.27), high number of medications (p < 0.001, OR = 1.26) and rheumatoid arthritis (p < 0.05, OR 2.55).

Conclusions

These findings reveal the recent bone health-related indications for BP prescription.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dennison E, Cole Z, Cooper C (2005) Diagnosis and epidemiology of osteoporosis. Curr Opin Rheumatol 17(4):456–461

    Article  PubMed  Google Scholar 

  2. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767

    Article  PubMed  Google Scholar 

  3. Delmas PD (2002) Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone 30:14–17

    Article  CAS  PubMed  Google Scholar 

  4. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX ™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397

    Article  CAS  PubMed  Google Scholar 

  5. Black DM, Cummings SR, Karpf DB, et al, for the Fracture Intervention Trial Research Group (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541

    Google Scholar 

  6. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077–2082

    Article  CAS  PubMed  Google Scholar 

  7. McClung MR, Geusens P, Miller PD, et al, for the Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340

    Google Scholar 

  8. Reginster J, Minne HW, Sorensen OH, for the Vertebral Efficacy with Risedronate Therapy (VERT) StudyGroup et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91

    Article  CAS  PubMed  Google Scholar 

  9. Bell NH, Johnson RH (1997) Bisphosphonates in the treatment of osteoporosis. Endocrine 6:203–206

    Article  CAS  PubMed  Google Scholar 

  10. McClung MR (2000) Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 1:225–238

    Article  CAS  PubMed  Google Scholar 

  11. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008

    Article  PubMed  Google Scholar 

  12. Silverman S (2006) Adherence to medications for the treatment of osteoporosis. Rheum Dis Clin North Am 32:721–731

    Article  PubMed  Google Scholar 

  13. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965–968

    Article  CAS  PubMed  Google Scholar 

  14. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153–159

    Article  CAS  PubMed  Google Scholar 

  15. Bischoff-Ferrari HA, Willet WC, Wong JB, Giovanucci E, Dietrich T, Dawson-Hughes B (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257–2264

    Article  CAS  PubMed  Google Scholar 

  16. Richy F, Ethgen O, Bruyere O, Reginster JY (2004) Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15:301–310

    Article  CAS  PubMed  Google Scholar 

  17. Bischoff-Ferrari HA, Dawson-Hughes B, Willet WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB (2004) Effect of vitamin D on falls: a meta-analysis. JAMA 291:1999–2006

    Article  CAS  PubMed  Google Scholar 

  18. Lee WL, Chao HT, Cheng MH, Wang PH (2008) Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas 60(2):92–107

    Article  CAS  PubMed  Google Scholar 

  19. Devogelaer JP (2004) A review of the effects of tibolone on the skeleton. Expert Opin Pharmacother 5(4):941–949

    Article  CAS  PubMed  Google Scholar 

  20. Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K (2005) Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study. Clin Rheumatol 24(3):232–238

    Article  PubMed  Google Scholar 

  21. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26(5):688–703

    Article  CAS  PubMed  Google Scholar 

  22. O’Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 3:CD005326

    PubMed  Google Scholar 

  23. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA (2006) The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 17(9):1404–1409

    Article  CAS  PubMed  Google Scholar 

  24. Honkanen R, Tuppurainen M, Alhava E, Saarikoski S (1991) Kuopio osteoporosis risk factor and prevention study. Baseline postal inquiry in 1989. Publications of the University of Kuopio, Community Health, Statistics and Reviews 3/1991

  25. Kröger H, Tuppurainen M, Honkanen R, Alhava E, Saarikoski S (1994) Bone mineral density and risk factors for osteoporosis-a population based study of 1600 perimenopausal women. Calcif Tissue Int 55:1–7

    Article  PubMed  Google Scholar 

  26. Komulainen MH, Kröger H, Tuppurainen MT, Heikkinen A-M, Alhava E, Honkanen R, Saarikoski S (1998) HRT and vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomised trial. Maturitas 31:45–54

    Article  CAS  PubMed  Google Scholar 

  27. WHO Scientific Group (1996) Research on the menopause in the 1990’s. A report of the WHO Scientific Group. World Health Organisation, Geneva, Switzerland 866:1–79

  28. Sandini L, Pentti K, Tuppurainen M, Kröger H, Honkanen R (2008) Agreement of self-reported estrogen use with prescription data: an analysis of women from Kuopio Osteoporosis Risk Factor and Prevention Study. Menopause 15(2):282–289

    Article  PubMed  Google Scholar 

  29. Honkanen K, Honkanen R, Heikkinen L, Kröger H, Saarikoski S (1999) The validity of self-reports of fractures in perimenopausal women. Am J Epidemiol 150:511–516

    CAS  PubMed  Google Scholar 

  30. Kröger H, Heikkinen J, Laitinen K, Kotaniemi A (1992) Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. Osteoporos Int 2:135–140

    Article  PubMed  Google Scholar 

  31. Dennerstein L, Smith AMA, Morse C, Burger H, Green A, Hopper J, Ryan M (1993) Menopausal symptoms in Australian women. Med J Aust 159:232–236

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was financially supported by the Academy of Finland (JS, MT) and Hulda Tossavainen Foundation (MK).

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Bone and Cartilage Research Unit (BCRU), University of Kuopio, Mediteknia Building, P.O. Box 1627, 70211, Kuopio, Finland

    J. Sirola, K. Salovaara, T. Rikkonen, M. Kärkkäinen, M. Tuppurainen, R. Honkanen & H. Kröger

  2. Department of Obstetrics and Gynaecology, Kuopio University Hospital, Kuopio, Finland

    M. Tuppurainen

  3. Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland

    J. S. Jurvelin

  4. Department of Orthopedics and Traumatology, Kuopio University Hospital, Kuopio, Finland

    J. Sirola, K. Salovaara & H. Kröger

Authors
  1. J. Sirola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Salovaara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Rikkonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Kärkkäinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Tuppurainen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. S. Jurvelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Honkanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Sirola.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sirola, J., Salovaara, K., Rikkonen, T. et al. Bone health-related factors and the use of bisphosphonates in community setting—15-year follow-up study. Osteoporos Int 22, 255–264 (2011). https://doi.org/10.1007/s00198-010-1254-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-010-1254-x

Keywords

Search

Navigation